CAU
ADPT icon

Caxton Associates (UK)’s Adaptive Biotechnologies ADPT Stock Holding History

Caxton Associates (UK)’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-36,035
Closed -$500K – 738
2026
Q1 		$500K Sell
36,035
-44,382
-55% -$707K 0.01% 502
2025
Q4 		$1.31M Buy
80,417
+3,218
+4% +$52.5K 0.03% 297
2025
Q3 		$1.15M Buy
+77,199
New +$941K 0.03% 310
2025
Q2 		– Sell
-12,475
Closed -$92.7K – 680
2025
Q1 		$92.7K Buy
+12,475
New +$95.9K ﹤0.01% 737

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Caxton Associates (UK)'s ADPT Position: Q2 2026 in Review

Caxton Associates (UK) sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 36,035 shares — an estimated $500K sold.

Caxton Associates (UK) first reported a position in ADPT in Q1 2025 and held it in 4 quarters. The position peaked at $1.31M in Q4 2025. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Caxton Associates (UK) reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 36,035 Adaptive Biotechnologies shares in Q2 2026, an estimated $500K.
  • Caxton Associates (UK) first reported a position in Adaptive Biotechnologies in Q1 2025 and held it in 4 quarters.
  • Caxton Associates (UK)'s Adaptive Biotechnologies position peaked at $1.31M in Q4 2025.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.